Amlodipine: Pediatric drug information

For additional information see "Amlodipine: Drug information" and "Amlodipine: Patient drug information"

For abbreviations, symbols, and age group definitions show table

Brand Names: US

Katerzia;
Norliqva;
Norvasc

Brand Names: Canada

ACH-Amlodipine;
AG-AmLODIPine;
APO-AmLODIPine;
Auro-AmLODIPine;
BIO-AmLODIPine;
DOM-AmLODIPine [DSC];
JAMP-AmLODIPine;
M-Amlodipine;
Mar-AmLODIPine;
MINT-AmLODIPine;
MYLAN-AmLODIPine;
Norvasc;
NRA-Amlodipine;
PDP-Amlodipine;
PHARMA-AmLODIPine;
PMS-AmLODIPine;
PRZ-Amlodipine;
RIVA-AmLODIPine;
SANDOZ AmLODIPine;
SANDOZ-AmLODIPine;
Septa-AmLODIPine [DSC];
TARO-Amlodipine;
TEVA AmLODIPine;
TEVA-AmLODIPine [DSC]

Therapeutic Category

Antianginal Agent;
Antihypertensive Agent;
Calcium Channel Blocker;
Calcium Channel Blocker, Dihydropyridine

Dosing: Pediatric

Hypertension

Hypertension:

Children <6 years: Limited data available: Oral: Initial: 0.1 mg/kg/dose once daily; titrate based on clinical response; maximum daily dose: 0.6 mg/kg/day or 5 mg/day (Ref).

Children ≥6 years and Adolescents: Oral: Initial: 2.5 mg once daily; titrate based on clinical response; maximum daily dose: 10 mg/day (Ref).

Raynaud phenomenon, treatment

Raynaud phenomenon, treatment: Very limited data available:

Children ≥6 years and Adolescents: Oral: Usual dosage range: 2.5 to 10 mg once daily; start dose low and increase as tolerated and based on symptom response (Ref). Note: In addition to nonpharmacologic interventions (eg, cold avoidance), dihydropyridine calcium channel blockers are recommended for management; although nifedipine has the most data and is generally used first-line, amlodipine is an acceptable alternative (Ref).

Dosing: Kidney Impairment: Pediatric

Children ≥6 years and Adolescents: No dosage adjustment necessary.

Dosing: Liver Impairment: Pediatric

There are no pediatric-specific dosage adjustments provided in the manufacturer's labeling; based on prolonged half-life in severe hepatic impairment and experience in adult patients, dosing adjustment and slow titration suggested.

Dosing: Adult

(For additional information see "Amlodipine: Drug information")

Angina

Angina:

Chronic stable angina (alternative agent):

Note: A beta-blocker is the preferred initial therapy; if there are ongoing symptoms on beta-blocker therapy, a long acting dihydropyridine calcium channel blocker (eg, amlodipine) may be added; amlodipine may also be used as an alternative therapy if there are contraindications or unacceptable adverse effects with beta-blockade (Ref).

Oral: 5 to 10 mg once daily.

Vasospastic angina:

Note: May use alone or in combination with nitrates (Ref).

Oral: 5 to 10 mg once daily.

Hypertension, chronic

Hypertension, chronic:

Note: For patients who warrant combination therapy (BP >20/10 mm Hg above goal or suboptimal response to monotherapy), may use with another appropriate agent (eg, angiotensin-converting enzyme [ACE] inhibitor, angiotensin II receptor blocker [ARB], or thiazide diuretic) (Ref).

Oral: Initial: 2.5 to 5 mg once daily; evaluate response after ~2 to 4 weeks and titrate dose, as needed, up to a maximum of 10 mg once daily; if additional blood pressure control is needed, consider combination therapy (Ref); antihypertensive effect attenuates with higher doses and adverse effects may become more prominent. Patients with severe asymptomatic hypertension and no signs of acute end organ damage should be evaluated for medication titration within 1 week (Ref).

Raynaud phenomenon

Raynaud phenomenon (off-label use): Oral: 5 mg once daily; if needed, increase dose gradually based on patient response and tolerability, usually once every 4 weeks, but not more frequently than once every 7 to 10 days; monitor blood pressure closely with each dose increase; maximum dose: 20 mg/day (Ref).

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

Altered kidney function: Mild to severe impairment: No dosage adjustment necessary (Ref).

Hemodialysis, intermittent (thrice weekly): Poorly dialyzed: No supplemental dose or dosage adjustment necessary (Ref).

Peritoneal dialysis: No dosage adjustment necessary (Ref).

CRRT: No dosage adjustment necessary (Ref).

PIRRT (eg, sustained, low-efficiency diafiltration): No dosage adjustment necessary (Ref).

Dosing: Liver Impairment: Adult

The liver dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Matt Harris, PharmD, MHS, BCPS, FAST; Jeong Park, PharmD, MS, BCTXP, FCCP, FAST; Arun Jesudian, MD; Sasan Sakiani, MD.

Note: Elimination half-life is approximately doubled and AUC increased ~1.4 times in patients with Child-Turcotte-Pugh class A (Ref). Calcium channel blockers may produce additional mesenteric vasodilation that may worsen portopulmonary hypertension especially in severe liver insufficiency (Ref).

Liver impairment prior to treatment initiation:

Initial or dose adjustment in patients with preexisting liver cirrhosis:

Child-Turcotte-Pugh class A to B: Oral: Initial: 2.5 mg once daily; if needed, may increase dose based on tolerability and response in increments of 2.5 mg/day, no more frequently than every 14 days; maximum dose: 10 mg/day (Ref).

Child-Turcotte-Pugh class C: Avoid use (Ref).

Liver impairment developing in patient already receiving amlodipine:

Chronic disease progression (eg, outpatient):

Baseline to Child-Turcotte-Pugh class A to C: No dosage adjustment necessary; if needed, adjust dose based on response (eg, blood pressure target) and tolerability (Ref).

Acute worsening of liver function (eg, requiring hospitalization):

Baseline to Child-Turcotte-Pugh class A to C: No dosage adjustment necessary; if needed, adjust dose based on response (eg, blood pressure target) and tolerability (Ref).

Adverse Reactions (Significant): Considerations

Peripheral edema

Peripheral edema is the most common adverse reaction with amlodipine, characterized by ankle and leg swelling independent of fluid retention (Ref). It is a bothersome adverse reaction for patients and may lead to discontinuation (Ref). Peripheral edema can be expected to subside within several days following intervention.

Mechanism: Dose-and time-related; related to the pharmacologic action. Calcium channel blocker-mediated peripheral edema is caused by arteriolar vasodilation that subsequently leads to increased hydrostatic pressure in the precapillary circulation and fluid movement from the capillary vasculature to the interstitial space (Ref). In addition, impaired postural vasoconstriction may contribute (Ref).

Onset: Varied; has been reported between 4 weeks to >6 months after initiation (Ref).

Risk factors:

• Dose-related; doses of 2.5 to 5 mg resulted in lower rates of edema versus 10 mg (Ref); however, may develop more frequently and at lower doses in patients with impaired postural autoregulation (eg, diabetes, arterial disease) (Ref).

• Duration-related (>6 months) (Ref)

• Females

• Dihydropyridine calcium channel blockers (DHPs) versus non-DHPs (Ref)

• Lipophilic DHPs (Ref)

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

>10%: Cardiovascular: Peripheral edema (2% to 11%, dose related; females: 15%; males: 6%) (table 1)

**Amlodipine: Adverse Reaction: Peripheral Edema**
Drug (Amlodipine)	Placebo	Population	Dose	Number of Patients (Amlodipine)	Number of Patients (Placebo)
15%	5%	Females	N/A	512	336
6%	1%	Males	N/A	1,218	914
11%	0.6%	N/A	10 mg/day	268	520
3%	0.6%	N/A	5 mg/day	296	520
2%	0.6%	N/A	2.5 mg/day	275	520

1% to 10%:

Cardiovascular: Flushing (≤3%, dose related, more frequent in females), palpitations (≤5%, dose related, more frequent in females)

Dermatologic: Pruritus (≤2%), skin rash (≤2%)

Gastrointestinal: Abdominal pain (2%), nausea (3%)

Genitourinary: Male sexual disorder (≤2%)

Nervous system: Asthenia (≤2%), dizziness (doses ≥5 mg/day: 3%), drowsiness (1% to 2%), fatigue (5%)

Neuromuscular & skeletal: Muscle cramps (≤2%)

Respiratory: Dyspnea (≤2%)

<1%:

Cardiovascular: Peripheral ischemia, sinus tachycardia, syncope, vasculitis

Dermatologic: Diaphoresis, erythema multiforme

Endocrine & metabolic: Hot flash, hyperglycemia, weight gain, weight loss

Gastrointestinal: Anorexia, constipation, dysphagia, flatulence, gingival hyperplasia, pancreatitis, vomiting, xerostomia

Genitourinary: Difficulty in micturition, female sexual disorder, nocturia, urinary frequency

Hematologic & oncologic: Leukopenia, purpuric disease, thrombocytopenia (Ref)

Hypersensitivity: Angioedema, hypersensitivity reaction

Nervous system: Abnormal dreams, anxiety, depersonalization, depression, hypoesthesia, insomnia, malaise, pain, paresthesia, peripheral neuropathy, rigors, tremor, vertigo

Neuromuscular & skeletal: Arthralgia, back pain, myalgia, osteoarthritis

Ophthalmic: Conjunctivitis, diplopia, eye pain

Otic: Tinnitus

Respiratory: Epistaxis

Postmarketing:

Cardiovascular: Atrioventricular node dysfunction (BRASH syndrome: Bradycardia, renal failure syndrome, atrioventricular block, shock, hyperkalemia) (Ref)

Dermatologic: Dermatologic disorder (Schamberg's disease) (Ref), psoriasis (Ref), toxic epidermal necrolysis (Ref)

Endocrine & metabolic: Gynecomastia (Ref)

Gastrointestinal: Gingival hyperplasia (Ref)

Hepatic: Ascites (Ref), cholestatic hepatitis (Ref), hepatotoxicity (Ref)

Nervous system: Akathisia (Ref), parkinsonism (Ref), tardive dystonia (Ref)

Neuromuscular & skeletal: Subacute cutaneous lupus erythematosus (Ref)

Renal: Acute interstitial nephritis (Ref)

Contraindications

Hypersensitivity to amlodipine or any component of the formulation.

Canadian labeling: Additional contraindications (not in the US labeling): Hypersensitivity to other dihydropyridines; severe hypotension (systolic BP <90 mm Hg); breastfeeding; shock (including cardiogenic shock); obstruction of the outflow tract of the left ventricle (eg, high-grade aortic stenosis); hemodynamically unstable heart failure after acute myocardial infarction; hereditary fructose intolerance (oral solution); hyperglycerolemia or glycerol kinase deficiency (oral solution).

Warnings/Precautions

Concerns related to adverse effects:

• Hypotension: Symptomatic hypotension can occur; acute hypotension upon initiation is unlikely due to the gradual onset of action. Blood pressure must be lowered at a rate appropriate for the patient's clinical condition.

Disease-related concerns:

• Aortic stenosis: Use amlodipine with extreme caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia.

• Heart failure: With the exception of amlodipine, calcium channel blockers should be avoided whenever possible in patients with heart failure with reduced ejection fraction (HFrEF). Amlodipine may be used for the treatment of hypertension or ischemic heart disease in patients with HFrEF, but has no effect on functional status or mortality (AHA/ACC/HFSA [Heidenreich 2022]).

• Hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment; may require lower starting dose; avoid use in patients with severe hepatic impairment. Also, may worsen portopulmonary hypertension especially in severe liver insufficiency (Bozbas 2016).

• Hypertrophic cardiomyopathy with left ventricular outflow tract obstruction: Use amlodipine with caution in patients with hypertrophic cardiomyopathy and left ventricular outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition (AHA/ACC [Ommen 2024]).

Dosage form specific issues:

• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity ("gasping syndrome") in neonates; the "gasping syndrome" consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP 1997; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.

• Ethanol: Oral solution contains 4% v/v ethyl alcohol.

• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.

Special populations:

• Older adult: Initiate at a lower dose in the elderly.

Other warnings/precautions:

• Titration: Peak antihypertensive effect is delayed; dosage titration should occur after 7 to 14 days on a given dose.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Oral, as besylate [strength expressed as base]:

Norliqva: 1 mg/mL (150 mL) [contains alcohol, usp]

Suspension, Oral, as benzoate [strength expressed as base]:

Katerzia: 1 mg/mL (150 mL) [contains polysorbate 80, sodium benzoate]

Tablet, Oral, as besylate [strength expressed as base]:

Norvasc: 2.5 mg, 5 mg, 10 mg

Generic: 2.5 mg, 5 mg, 10 mg

Generic Equivalent Available: US

May be product dependent

Pricing: US

Solution (Norliqva Oral)

1 mg/mL (per mL): $4.12

Suspension (Katerzia Oral)

1 mg/mL (per mL): $5.12

Tablets (amLODIPine Besylate Oral)

2.5 mg (per each): $0.06 - $1.92

5 mg (per each): $0.06 - $1.93

10 mg (per each): $0.07 - $2.38

Tablets (Norvasc Oral)

2.5 mg (per each): $10.37

5 mg (per each): $10.37

10 mg (per each): $14.22

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Oral, as besylate [strength expressed as base]:

Generic: 1 mg/mL (150 mL)

Tablet, Oral, as besylate [strength expressed as base]:

Norvasc: 5 mg, 10 mg

Generic: 2.5 mg, 5 mg, 10 mg

Extemporaneous Preparations

Note: Commercial oral liquid preparations are available (1 mg/mL).

1 mg/mL Oral Suspension

A 1 mg/mL oral suspension may be made with tablets and either a 1:1 mixture of simple syrup and 1% methylcellulose or a 1:1 mixture of Ora-Plus and Ora-Sweet. Crush fifty 5 mg tablets in a mortar and reduce to a fine powder. Add small portions of the chosen vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to almost 250 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 250 mL. Label "shake well" and "refrigerate". Stable for 56 days at room temperature or 91 days refrigerated.

Nahata MC, Morosco RS, and Hipple TF. Stability of Amlodipine Besylate in Two Liquid Dosage Forms. J Am Pharm Assoc (Wash). 1999;39(3):375-377.10363465

Administration: Pediatric

The following feeding tube recommendations are based upon the best available evidence and clinical expertise. Senior editor panel: Joseph I. Boullata, PharmD, RPh, CNS-S, FASPEN, FACN; Peggi A. Guenter, PhD, RN, FASPEN; Kathleen Gura, PharmD, BCNSP, FASHP, FASPEN, FPPA, FMSHP; Mark G. Klang, MS, RPh, BCNSP, PhD, FASPEN; Linda Lord, NP, ACNP-BC, CNSC, FASPEN.

Note: Recommendations may not account for differences in inactive ingredients, osmolality, or other formulation properties that may vary among products from different manufacturers.

Oral: May be administered without regard to food.

Oral solution (commercially available): Administer with an accurate measuring device (calibrated oral syringe or measuring cup); do not use a household teaspoon or tablespoon to measure dose (overdosage may occur).

Administration via feeding tube:

Gastric (eg, NG, G-tube) or post-pyloric tubes (eg, J-tube): Dilute dose with at least an equivalent volume of purified water to reduce osmolality and viscosity; some experts recommend diluting in a volume of purified water that is twice the amlodipine solution volume (eg, 10 mL amlodipine solution diluted in 20 mL purified water) immediately prior to administering. Draw up diluted solution into enteral dosing syringe and administer via feeding tube (Ref).

Dosage form information: Undiluted Norliqva has a reported osmolality of ~1,476 mOsm/kg (per the manufacturer); oral solutions with an osmolality >600 mOsm/kg may increase the probability of adverse GI effects (eg, diarrhea, cramping, abdominal distention, slowed gastric emptying), particularly if administered post-pylorically, inadequately diluted, and/or used in at-risk patients (eg, neonates and infants, patients with short bowel syndrome) (Ref).

General guidance: Hold enteral nutrition during amlodipine administration (Ref). Flush feeding tube with the lowest volume of purified water necessary to clear the tube prior to administration based on size of patient and/or feeding tube (eg, neonates: 1 to 3 mL; infants and children: 2 to 5 mL; adolescents: 15 mL); refer to institutional policies and procedures (Ref). Following administration, rinse container used for preparation with purified water; draw up rinse and administer contents to ensure delivery of entire dose (Ref). Flush feeding tube with an appropriate volume of purified water and restart enteral nutrition (Ref).

Oral suspension (commercially available): Shake well before using. Administer with an accurate measuring device (calibrated oral syringe or measuring cup); do not use a household teaspoon or tablespoon to measure dose (overdosage may occur).

Administration via feeding tube:

Gastric (eg, NG, G-tube) or post-pyloric tubes (eg, J-tube): Shake suspension well prior to drawing up dose for dilution. Dilute dose in volume of purified water that is twice the amlodipine suspension volume (eg, 10 mL amlodipine suspension diluted in 20 mL purified water) immediately prior to administration. Draw up diluted suspension into enteral dosing syringe and administer via feeding tube (Ref).

Dosage form information: Although there is no information available on the osmolality of amlodipine oral suspension, this product may have elevated osmolality which could impact tolerance; consider the potential risks versus benefits prior to use (Ref).

Tablets :

Administration via feeding tube:

Gastric tubes (eg, NG, G-tube) or post-pyloric tubes (eg, J-tube) (≥8 French): Crush and disperse tablet in 10 mL purified water; draw up mixture into enteral dosing syringe and administer via feeding tube (Ref).

Administration: Adult

Oral: Administer without regard to meals. Shake suspension well before using. Administer with an accurate measuring device (calibrated oral syringe or measuring cup); do not use a household teaspoon to measure dose.

Enteral feeding tube:

The following recommendations are based upon the best available evidence and clinical expertise. Senior editorial team: Joseph I. Boullata, PharmD, RPh, CNS-S, FASPEN, FACN; Peggi A. Guenter, PhD, RN, FASPEN; Kathleen Gura, PharmD, BCNSP, FASHP, FASPEN, FPPA, FMSHP; Mark G. Klang, MS, RPh, BCNSP, PhD, FASPEN; Linda Lord, NP, ACNP-BC, CNSC, FASPEN.

Oral solution (commercially available):

Gastric (eg, NG, G-tube ) or post-pyloric (eg, J-tube) tubes: Dilute dose with at least an equivalent volume of purified water prior to administering to reduce osmolality and viscosity; some experts recommend diluting in a volume of purified water that is twice the amlodipine solution volume (eg, 10 mL amlodipine solution diluted in 20 mL purified water) immediately prior to administration. Draw up diluted solution into enteral dosing syringe and administer via feeding tube (Ref).

Dosage form information: One undiluted oral solution has been reported to have an osmolality of ~1,500 mOsm/kg (per the manufacturer); oral solutions with an osmolality >600 mOsm/kg may increase the probability of adverse GI effects (eg, diarrhea, cramping, abdominal distention, slowed gastric emptying), particularly if administered post-pylorically, inadequately diluted, and/or used in at-risk patients (eg, neonates and infants, patients with short bowel syndrome) (Ref).

General guidance: Hold enteral nutrition during amlodipine administration (Ref). Flush feeding tube with an appropriate volume of purified water (eg, 15 mL) before administration (Ref). Following administration, rinse container used for preparation with purified water; draw up rinse and administer contents to ensure delivery of entire dose (Ref). Flush feeding tube with an appropriate volume of purified water (eg, 15 mL) and restart enteral nutrition (Ref).

Oral suspension (commercially available):

Gastric (eg, NG, G-tube) or post-pyloric (eg, J-tube) tubes: Shake suspension well prior to drawing up dose for dilution. Dilute dose in volume of purified water that is twice the amlodipine suspension volume (eg, 10 mL amlodipine suspension diluted in 20 mL purified water) immediately prior to administration. Draw up diluted suspension into enteral dosing syringe and administer via feeding tube (Ref).

Oral tablets:

Gastric (eg, NG, G-tube) or post-pyloric (eg, J-tube) tubes (≥8 French): Crush and disperse tablet in 10 mL purified water; draw up mixture into enteral dosing syringe and administer via feeding tube (Ref).

No te: Recommendations may not account for differences in inactive ingredients, osmolality, or other formulation properties among manufacturers.

Storage/Stability

Solution: Store at 20°C to 25°C (68°F to 77°F); excursion permitted to 15°C to 30°C (59°F to 86°F). Store and dispense in original container.

Suspension: Store at 2°C to 8°C (36°F to 46°F); avoid freezing and excessive heat. Protect from light.

Tablets: Store at 15°C to 30°C (59°F to 86°F).

Use

Treatment of hypertension (FDA approved in ages ≥6 years and adults); chronic stable angina (FDA approved in adults); vasospastic (Prinzmetal) angina (FDA approved in adults); angiographically documented coronary artery disease (to decrease risk of hospitalization [due to angina] and coronary revascularization procedure) (FDA approved in adults); has also been used in the treatment of Raynaud phenomenon.

Medication Safety Issues

Sound-alike/look-alike issues:

AmLODIPine may be confused with aMILoride

Norvasc may be confused with Navane, Norvir, Vascor

High alert medication:

The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs (pediatric liquid medications requiring measurement) which have a heightened risk of causing significant patient harm when used in error (High-Alert Medications in Community/Ambulatory Care Settings).

International issues:

Norvasc [US, Canada, and multiple international markets] may be confused with Vascor brand name for imidapril [Philippines] and simvastatin [Malaysia, Singapore, and Thailand]

Older Adult: High-Risk Medication:

Amlodipine is identified in the Screening Tool of Older Person's Prescriptions (STOPP) criteria as a potentially inappropriate medication in older adults (≥65 years of age) with symptomatic aortic stenosis (O’Mahony 2023).

Metabolism/Transport Effects

Substrate of CYP3A4 (Major with inhibitors), CYP3A4 (Minor with inducers); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; Inhibits CYP3A4 (Weak);

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program

Alfuzosin: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

ALPRAZolam: CYP3A4 Inhibitors (Weak) may increase serum concentration of ALPRAZolam. Risk C: Monitor

Amifostine: Blood Pressure Lowering Agents may increase hypotensive effects of Amifostine. Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine. Risk D: Consider Therapy Modification

Amphetamines: May decrease antihypertensive effects of Antihypertensive Agents. Risk C: Monitor

Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may increase hypotensive effects of Antipsychotic Agents (Second Generation [Atypical]). Risk C: Monitor

Arginine: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Atosiban: Calcium Channel Blockers may increase adverse/toxic effects of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea. Risk C: Monitor

Barbiturates: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Benperidol: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Brigatinib: May decrease antihypertensive effects of Antihypertensive Agents. Brigatinib may increase bradycardic effects of Antihypertensive Agents. Risk C: Monitor

Brimonidine (Topical): May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Bromperidol: May decrease hypotensive effects of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may increase hypotensive effects of Bromperidol. Risk X: Avoid

Calcium Salts: May decrease therapeutic effects of Calcium Channel Blockers. Risk C: Monitor

CarBAMazepine: CYP3A4 Inhibitors (Weak) may increase serum concentration of CarBAMazepine. Risk C: Monitor

Charcoal, Activated: May decrease serum concentration of AmLODIPine. Risk C: Monitor

Clofazimine: May increase serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor

CycloSPORINE (Systemic): Calcium Channel Blockers (Dihydropyridine) may increase serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase serum concentration of Calcium Channel Blockers (Dihydropyridine). Risk C: Monitor

CYP3A4 Inducers (Moderate): May decrease serum concentration of AmLODIPine. Risk C: Monitor

CYP3A4 Inducers (Strong): May decrease serum concentration of AmLODIPine. Risk C: Monitor

CYP3A4 Inhibitors (Moderate): May increase serum concentration of AmLODIPine. Risk C: Monitor

CYP3A4 Inhibitors (Strong): May increase serum concentration of AmLODIPine. Risk C: Monitor

Dantrolene: May increase hyperkalemic effects of Calcium Channel Blockers. Dantrolene may increase negative inotropic effects of Calcium Channel Blockers. Risk X: Avoid

Dapoxetine: May increase orthostatic hypotensive effects of Calcium Channel Blockers. Risk C: Monitor

Dexmethylphenidate: May decrease therapeutic effects of Antihypertensive Agents. Risk C: Monitor

Diazoxide: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

DULoxetine: Blood Pressure Lowering Agents may increase hypotensive effects of DULoxetine. Risk C: Monitor

Finerenone: CYP3A4 Inhibitors (Weak) may increase serum concentration of Finerenone. Risk C: Monitor

Flibanserin: CYP3A4 Inhibitors (Weak) may increase serum concentration of Flibanserin. Risk C: Monitor

Flunarizine: May increase therapeutic effects of Antihypertensive Agents. Risk C: Monitor

Fusidic Acid (Systemic): May increase serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Consider avoiding this combination if possible. If required, monitor patients closely for increased adverse effects of the CYP3A4 substrate. Risk D: Consider Therapy Modification

Herbal Products with Blood Pressure Increasing Effects: May decrease antihypertensive effects of Antihypertensive Agents. Risk C: Monitor

Herbal Products with Blood Pressure Lowering Effects: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Hypotension-Associated Agents: Blood Pressure Lowering Agents may increase hypotensive effects of Hypotension-Associated Agents. Risk C: Monitor

Iloperidone: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Indoramin: May increase hypotensive effects of Antihypertensive Agents. Risk C: Monitor

Inhalational Anesthetics: May increase hypotensive effects of Calcium Channel Blockers. Risk C: Monitor

Isocarboxazid: May increase antihypertensive effects of Antihypertensive Agents. Risk X: Avoid

Ixabepilone: CYP3A4 Inhibitors (Weak) may increase serum concentration of Ixabepilone. Risk C: Monitor

Lemborexant: CYP3A4 Inhibitors (Weak) may increase serum concentration of Lemborexant. Management: The maximum recommended dosage of lemborexant is 5 mg, no more than once per night, when coadministered with weak CYP3A4 inhibitors. Risk D: Consider Therapy Modification

Levodopa-Foslevodopa: Blood Pressure Lowering Agents may increase hypotensive effects of Levodopa-Foslevodopa. Risk C: Monitor

Lomitapide: CYP3A4 Inhibitors (Weak) may increase serum concentration of Lomitapide. Management: Patients on lomitapide 5 mg/day may continue that dose. Patients taking lomitapide 10 mg/day or more should decrease the lomitapide dose by half. The lomitapide dose may then be titrated up to a max adult dose of 30 mg/day. Risk D: Consider Therapy Modification

Loop Diuretics: May increase hypotensive effects of Antihypertensive Agents. Risk C: Monitor

Lormetazepam: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Lovastatin: AmLODIPine may increase serum concentration of Lovastatin. Risk C: Monitor

Magnesium Sulfate: May increase adverse/toxic effects of Calcium Channel Blockers (Dihydropyridine). Specifically, the risk of hypotension or muscle weakness may be increased. Risk C: Monitor

Melatonin: May decrease antihypertensive effects of Calcium Channel Blockers (Dihydropyridine). Risk C: Monitor

Metergoline: May decrease antihypertensive effects of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may increase orthostatic hypotensive effects of Metergoline. Risk C: Monitor

Methylphenidate: May decrease antihypertensive effects of Antihypertensive Agents. Risk C: Monitor

Midazolam: CYP3A4 Inhibitors (Weak) may increase serum concentration of Midazolam. Risk C: Monitor

Molsidomine: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Naftopidil: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Neuromuscular-Blocking Agents (Nondepolarizing): Calcium Channel Blockers may increase neuromuscular-blocking effects of Neuromuscular-Blocking Agents (Nondepolarizing). Risk C: Monitor

Nicergoline: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Nicorandil: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

NiMODipine: CYP3A4 Inhibitors (Weak) may increase serum concentration of NiMODipine. Risk C: Monitor

Nitroprusside: Blood Pressure Lowering Agents may increase hypotensive effects of Nitroprusside. Risk C: Monitor

Obinutuzumab: May increase hypotensive effects of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion. Risk D: Consider Therapy Modification

Pentoxifylline: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Perazine: May increase hypotensive effects of Antihypertensive Agents. Risk C: Monitor

Pholcodine: Blood Pressure Lowering Agents may increase hypotensive effects of Pholcodine. Risk C: Monitor

Phosphodiesterase 5 Inhibitors: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Pimozide: CYP3A4 Inhibitors (Weak) may increase serum concentration of Pimozide. Risk X: Avoid

Prazosin: Antihypertensive Agents may increase hypotensive effects of Prazosin. Risk C: Monitor

Prostacyclin Analogues: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Quinagolide: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Red Yeast Rice: AmLODIPine may increase serum concentration of Red Yeast Rice. Risk C: Monitor

Silodosin: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Simvastatin: AmLODIPine may increase serum concentration of Simvastatin. Management: Dose of simvastatin should not exceed 20 mg daily if coadministering with amlodipine. If coadministering with simvastatin and amlodipine, close laboratory and clinical monitoring for signs and symptoms of rhabdomyolysis is warranted. Risk D: Consider Therapy Modification

Sincalide: Drugs that Affect Gallbladder Function may decrease therapeutic effects of Sincalide. Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction. Risk D: Consider Therapy Modification

Sirolimus (Conventional): CYP3A4 Inhibitors (Weak) may increase serum concentration of Sirolimus (Conventional). Risk C: Monitor

Sirolimus (Protein Bound): CYP3A4 Inhibitors (Weak) may increase serum concentration of Sirolimus (Protein Bound). Management: Reduce the dose of protein bound sirolimus to 56 mg/m² when used concomitantly with a weak CYP3A4 inhibitor. Risk D: Consider Therapy Modification

Tacrolimus (Systemic): Calcium Channel Blockers (Dihydropyridine) may increase serum concentration of Tacrolimus (Systemic). Risk C: Monitor

Tacrolimus (Systemic): CYP3A4 Inhibitors (Weak) may increase serum concentration of Tacrolimus (Systemic). Risk C: Monitor

Terazosin: Antihypertensive Agents may increase hypotensive effects of Terazosin. Risk C: Monitor

Triazolam: CYP3A4 Inhibitors (Weak) may increase serum concentration of Triazolam. Risk C: Monitor

Ubrogepant: CYP3A4 Inhibitors (Weak) may increase serum concentration of Ubrogepant. Management: In patients taking weak CYP3A4 inhibitors, the initial and second dose (given at least 2 hours later if needed) of ubrogepant should be limited to 50 mg. Risk D: Consider Therapy Modification

Urapidil: Antihypertensive Agents may increase hypotensive effects of Urapidil. Risk C: Monitor

Reproductive Considerations

Medications considered acceptable for the treatment of chronic hypertension during pregnancy may generally be used in patients trying to conceive. Amlodipine is not considered a preferred agent for use in pregnant patients; consider transitioning to a preferred agent in patients planning to become pregnant (ACC/AHA [Whelton 2018]; ACOG 2019; NICE 2019).

Pregnancy Considerations

Amlodipine crosses the placenta. Cord blood concentrations were ~40% of maternal serum at delivery, and concentrations in the newborn were below the limit of quantification (<0.1 ng/mL) when measured in eight infants within 48 hours of delivery (Morgan 2017; Morgan 2018).

Due to pregnancy-induced pharmacologic changes, amlodipine pharmacokinetics may be altered immediately postpartum (Morgan 2018; Naito 2015b; Taguchi 2019).

Chronic maternal hypertension is associated with adverse events in the fetus/infant. Chronic maternal hypertension may increase the risk of birth defects, low birth weight, premature delivery, stillbirth, and neonatal death. Actual fetal/neonatal risks may be related to the duration and severity of maternal hypertension. Untreated chronic hypertension may also increase the risks of adverse maternal outcomes, including gestational diabetes, preeclampsia, delivery complications, stroke, and myocardial infarction (ACOG 2019).

Patients with preexisting hypertension may continue their medication during pregnancy unless contraindications exist (ESC [Regitz-Zagrosek 2018]). When treatment of hypertension is initiated during pregnancy, agents other than amlodipine may be preferred (ACOG 2019; ESC [Cífková 2020]; ESC [Regitz-Zagrosek 2018]; SOGC [Magee 2022]).

Monitoring Parameters

Blood pressure, heart rate, liver enzymes.

Mechanism of Action

Inhibits calcium ion from entering the “slow channels” or select voltage-sensitive areas of vascular smooth muscle and myocardium during depolarization, producing a relaxation of coronary vascular smooth muscle and coronary vasodilation; increases myocardial oxygen delivery in patients with vasospastic angina. Amlodipine directly acts on vascular smooth muscle to produce peripheral arterial vasodilation reducing peripheral vascular resistance and blood pressure.

Pharmacokinetics (Adult Data Unless Noted)

Onset of action: Antihypertensive effect: Significant reductions in blood pressure at 24 to 48 hours after first dose; slight increase in heart rate within 10 hours of administration may reflect some vasodilating activity (Donnelly 1993).

Duration: Antihypertensive effect: At least 24 hours (Donnelly 1993); has been shown to extend to at least 72 hours when discontinued after 6 to 7 weeks of therapy (Biston 1999).

Absorption: Well absorbed (Meredith 1992).

Distribution: Mean V_d:

Children >6 years: Similar to adults on a mg per kg basis; Note: Weight-adjusted V_d in younger children (<6 years of age) may be greater than in older children (Flynn 2006).

Adults: 21 L/kg (Scholz 1997).

Protein binding: ~93%.

Metabolism: Hepatic (~90%) to inactive metabolites.

Bioavailability: 64% to 90%.

Half-life elimination: Terminal (biphasic): 30 to 52 hours.

Time to peak, plasma: 6 to 12 hours.

Excretion: Urine (10% of total dose as unchanged drug, 60% of total dose as metabolites).

Clearance: May be decreased in patients with hepatic insufficiency or moderate to severe heart failure; weight-adjusted clearance in children >6 years of age is similar to adults; Note: Weight-adjusted clearance in younger children (<6 years of age) may be greater than in older children (Flynn 2006).

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Hepatic function impairment: Following a single dose of amlodipine 5 mg in patients with Child-Turcotte-Pugh class A, the elimination half-life approximately doubled and AUC increased ~1.4 times (Abernathy 1989; Darnis 1993).

Older adult: AUC may increase ~40% to 60%.

Moderate to severe heart failure: AUC may increase ~40% to 60%.

Brand Names: International

International Brand Names by Country

For country code abbreviations (show table)

(AE) United Arab Emirates: Amlo | Amlocard | Amlopress | Amlosafe | Amlosin | Amneo | Istin | Lofral | Maldocardin | Norvasc | Stamlo | Vascodipine;
(AR) Argentina: Abloom | Amloc | Amlodicord | Amlodine | Amlodipina | Amlodipina Denver farma | Amlodipina ilab | Amlodipina richet | Amlodipina tauro | Amlodipina vannier | Amlodisane | Amlopaw | Amlosidane | Amlotens | Amze | Anexa | Angiofilina | Angipec | Arteriosan | Brancilina | Calpres | Cardivas | Cordiax | Coroval | Dronalden | Hipertensal | Ilduc | Indalten | Mitokor | Nexotensil | Nikor | Oteramina | Pelmec | Terloc | Tervalon | Verodipin | Zundic;
(AT) Austria: Amlodibene | Amlodilan | Amlodinova | Amlodipin 1a pharma gmbh | Amlodipin accord | Amlodipin actavis | Amlodipin arcana | Amlodipin Arcana | Amlodipin besilat stada | Amlodipin bluefish | Amlodipin G.L. | Amlodipin genericon pharma | Amlodipin hexal pharma | Amlodipin interpharm | Amlodipin mylan | Amlodipin Ratiopharm | Amlodipin sandoz | Amlodipin stada arzneimittel gmbh | Amlodipin Teva | Amlopin s | Amlotyrol | Coradipin | Norvasc;
(AU) Australia: Amlodipine | Amlodipine an | Amlodipine apotex | Amlodipine Drla | Amlodipine Generic Health | Amlodipine sandoz | Auro Amlodipine | Nordip | Norvapine | Norvasc | Noumed amlodipine | Ozlodip | Perivasc;
(BD) Bangladesh: Alopin | Amdin | Amdocal | Amdopin | Amlo | Amlocard | Amlodin | Amlohil | Amlopin | Amlopress | Amlosun | Amlovas | Amocal | Ampil | Ampre | Amtinol | Cab | Calchek | Calock | Calpin | Calpress | Calvasc | Camlodin | Cardifort | Cardipin | Cardolab | Cardosia | Ccb | Cordil | Cvnor | Dilopin | Dipicard | Dopin | Emlon | Hipre | Imped | Ipin | Locard | Lodipin | Lopin | Lovapres | Lovask | Nelod | Nopidin | Olipin | Pristin | Sb amlod | Sidopin | Vasopin | Vesocal | Xelcard;
(BE) Belgium: Amlodipin ab | Amlodipin besilaat sandoz | Amlodipine arrow | Amlodipine Besilaat Sandoz | Amlodipine Besilaate Sandoz | Amlodipine besilate Docpharma | Amlodipine Besilate EG | Amlodipine Besilate Ratiopharm | Amlodipine bexal | Amlodipine Ivowen | Amlodipine merck-generics | Amlodipine ratiopharm | Amlodipine sandoz | Docamlodipine | Provasc | Tenox;
(BF) Burkina Faso: Amapine | Amep | Amlibon | Amlo denk | Amlo h | Amloclass | Amlong | Amlonorm | Amlopres | Amlor | Amlostar | Amlowin | Calcheck | Circagard | Fairdipin | Lofral | Lopin;
(BG) Bulgaria: Accel | Agen | Amlocor | Amlodicon | Amlodigamma | Amlodipin | Amlodipine biopharm | Amlodipine ecopharm | Amlodipine Medica | Amlopin | Amloteron | Amlovask | Neodipin Bes T | Normodipin | Norvasc | Tenox;
(BR) Brazil: Alivpress | Amelovas | Amilopil | Amlocor | Amlodil | Amloprax | Amlovasc | Anlo | Anlodibal | Anlodil | Anlusbed | Besilapin | Besilato de anlodipino | Cordarex | Cordipina | Lodipen | Lodipil | Nemodine | Nicord | Norvasc | Pressat | Roxflan | Tenlopin | Tensaliv | Tensidipin | Tensodin;
(CH) Switzerland: Amlo | Amlo eco | Amlodipin Actavis | Amlodipin Axapharm | Amlodipin besilat 1 a pharma | Amlodipin Besilat Teva | Amlodipin Cimex | Amlodipin HelvePharm | Amlodipin Orion | Amlodipin Pfizer | Amlodipin sandoz eco | Amlodipin Spirig | Amlodipin spirig hc | Amlodipin viatris | Amlodipin Zentiva | Amlodipin-Mepha | Norvasc;
(CI) Côte d'Ivoire: Amaday | Amapine | Amcard | Amep | Amilo | Amlibon | Amlo h | Amlocor | Amlodipine | Amlodis | Amlong | Amlopres | Amlor | Amlostar | Amlotensine | Amlowel | Amlowin | Amoclass | Anglor | Asomex | Calcinib | Creadipine | Gardilong | Lopine | Pimlo | Ronamlo | Varinil | Zocard;
(CL) Chile: Amdipin | Amloc | Amlodipino | Ampino | Avirin | Lomakare | Molsicor | Norvasc | Presilam | Presovasc | Terloc;
(CN) China: Amlodipine | Amlodipine besylate | An nei zhen | Ao wan lu | Aspartic acid amlodipine | Bi luo ping | Jing xin | Jiu bao shu | Ke ping | Lan di | Li si de | Luo he xi | Mai li ping | Ming yi | Ning li ping | Norvasc | Nuo er ma | Pu luo xin xi | Sa bo ni | Sai li de | Shen yi kang lin | Shu le kang | Tian wu | Xi luo ning | XinLuoPing | Ya bang bei di | Ya shi da | Ya si ke ping | Yi lu jing;
(CO) Colombia: Abalpin | Alidona | Amcardia | Amdipin | Amigard | Amlodip | Amlodipino | Amlodipino MK | Amlosyn | Amlovas | Cardinor | Eucoran | Micior | Norvas | Rivam | Samlopharis | Vasten;
(CR) Costa Rica: Amlodin raven | Amlodipino | Istin;
(CZ) Czech Republic: Afiten | Agen | Alozur | Amilostad | Amlodipin | Amlodipin accord | Amlodipin Actavis | Amlodipin aurovitas | Amlodipin bluefish | Amlodipin hbf | Amlodipin mylan | Amlodipin Orion | Amlodipin Teva | Amlodipin vitabalans | Amlopp | Amloratio | Amlozek | Apo amlo | Cardilopin | Hipres | Normodipine | Norvasc | Orcal | Orcal Neo | Recotens | Torella | Zeppeliton | Zorem;
(DE) Germany: Amlo | Amlo denk | Amlo Q | Amlo Q besilat | Amlo Teva | Amlo wolff | Amlobesilat | Amlobeta mesilat | Amlocard | Amloclair | Amlodigamma top | Amlodipin | Amlodipin (besilat) Dexcel | Amlodipin abz | Amlodipin accedo | Amlodipin Acino | Amlodipin actavis | Amlodipin aurobindo | Amlodipin awd | Amlodipin basics | Amlodipin Besilat Heumann | Amlodipin Corax | Amlodipin dexcel | Amlodipin dura | Amlodipin fair-med | Amlodipin hec pharm | Amlodipin hexal | Amlodipin Ivax | Amlodipin mesilate | Amlodipin puren | Amlodipin q-pharm | Amlodipin Ratiopharm | Amlodipin sandoz | Amlodipin stada | Amlodipin Volkspharma | Amlodipin von ct | Amlodipin Winthrop | Amlolich | Amparo | Norvas | Norvasc | Sigamlo;
(DK) Denmark: Amlodipin 1a farma | Amlodipin actavis | Amlodipin Alpharma | Amlodipin Alternova | Amlodipin Arrow | Amlodipin Copyfarm | Amlodipin Gea | Amlodipin hexal | Amlodipin Pfizer | Amlodipin Ratiopharm | Amlohexal | Amlopharm;
(DO) Dominican Republic: Aloten | Amapine | Amlibon | Amloblock | Amlobrit | Amlocardi | Amlocol | Amlodipina | Amlodipina besilat | Amlodipina Lam | Amlodipine | Amlodipino | Amlofel | Amloseven | Amlosyn | Amlovas | Ampliron | Ampres | Amtas | Asomex | Cardicol | Carpin | Corameys | Diasis | Lochem | Lodipar | Lodipin | Lodipres | Maxidipin | Nor-Lodipina | Norvasc | Perten | Premina | Presodip | Stein novopres | Vasocal | Vasonil;
(EC) Ecuador: Amdipin | Amlibon | Amlion | Amlodipina | Amlodipina besilato | Amlodipina Mepha | Amlodipino | Amlodipino MK | Amlodipino nifa | Amlodipino-R | Amlodisane | Amlor | Amlosyn | Amlovid | Ampliron | Besilato de amlodipina | Cardiopine | Goritel | Kairopine | Lodipar | Noloten | Nordipax | Normapres | Norvasc | Raserdipina | Stamlo | Udp | Vamlo | Vasocal | Vasodil | Vasonorm | Vasotop | Zidane;
(EE) Estonia: Agen | Amlocard | Amlodipin Ratiopharm | Amlodipine Accord | Amlodipine teva | Amlodipine vitabalans | Hipres | Lofral | Normodipin | Norvasc;
(EG) Egypt: Adcodipine | Alkapress | Amilo | Amlodipine | Amlor | Amlowest | Cardiovasc | Coronavine | Dipotensive | Myodura | Norvasc | Pinavasc | Regcor | Vasonorm | Vasopine | Windipine;
(ES) Spain: Amlodipino | Amlodipino accord | Amlodipino Actavis | Amlodipino Almus | Amlodipino alter | Amlodipino Aphar | Amlodipino Apotex | Amlodipino Aurobindo | Amlodipino aurovitas | Amlodipino bexal | Amlodipino Bluefish | Amlodipino combix | Amlodipino Cuvefar | Amlodipino Korhispana | Amlodipino Lareq | Amlodipino Mabo | Amlodipino Mylan | Amlodipino mylan pharmaceuticals | Amlodipino Normon | Amlodipino pharmacia | Amlodipino Pharmagenus | Amlodipino Ranbaxy | Amlodipino Ratiomed | Amlodipino Ratiopharm | Amlodipino sandoz | Amlodipino Stada | Amlodipino Tarbis | Amlodipino Tecnigen | Amlodipino Teva | Amlodipino ur | Amlodipino vir | Amlodipino vir pharma | Amlodipino winthrop | Arainno | Astudal | Norvas | Zabart;
(ET) Ethiopia: Amcardia | Amlibon | Amlo denk | Amlocor | Amlodin | Amlodipine | Amlodipine besylate | Amlodipino vir pharma | Amlopin | Amlorine | Amodep | Anlodin | Hovasc | Klodip | Norvasc;
(FI) Finland: Amlodipin | Amlodipin accord | Amlodipin bluefish | Amlodipin bmm pharma | Amlodipin Enna | Amlodipin generics | Amlodipin hexal | Amlodipin Ivax | Amlodipin krka | Amlodipin Orifarm | Amlodipin Ranbaxy | Amlodipin Ratiopharm | Amlodipine vitabalans | Amlodorion | Amloratio | Norvasc;
(FR) France: Amlodipine arrow | Amlodipine cevidra | Amlodipine krka | Amlodipine rosemont | Tenox;
(GB) United Kingdom: Amlodipine | Amlodipine Accord | Amlodipine arrow | Istin;
(GH) Ghana: Amlocad | Amlodose | Amlonova | Lg Amlodac | Randip | Ronamlo;
(GR) Greece: Agen | Amlibon | Amlodipine | Amlodipine besilate teva | Amlodipine besilate/Teva | Amlotens | Nolvac | Nordex | Normodin | Norvagen;
(HK) Hong Kong: A-Phine | Amdivasc | Amdocal | Amedin | Amlocor | Amlodigamma | Amlodipina Farmoz | Amlodipine gp | Amlodipine sandoz | Amlodipine teva | Amlong | Amlopin | Amlorine | Amlotens | Amlozen | Amodep | Amtas | Apo amlodipine | Cp lovac | Emlip | Hovasc | Lofral | Lomakline | Lopicard | Norvasc | Pms Amlodipine | Stadovas | Zynor;
(HR) Croatia: Almirin | Amlodipin Cipla | Amlodipin Genera | Amlodipin Genericon | Amlodipin PharmaS | Amlodipin sandoz | Amlopin | Amonex | Caprez | Doremis | Lopin | Norvasc | Tenox | Vilpin;
(HU) Hungary: Alozur | Amlipin | Amlobesyl | Amlodep | Amlodipin bezilat ratiopharm | Amlodipin mylan | Amlodipin Pharma Regist | Amlodipin pharma vim | Amlodipin Ratiopharm | Amlodipin Teva | Amlodipin vitabalans | Amlodipress 1 A Pharma | Amlozek | Cardilopin | Normodipine | Norvasc | Tenox;
(ID) Indonesia: A B Vask | Amcor | Amdixal | Amlocor | Amlodipine | Amlodipine besylate | Amlodipine besylate 10 | Amlogal | Amlogrix | Amloten | Belvas | Bufacardo | Calsivas | Comdipin | Corvask | Cydipin | Dilavask | Divask | Ethivask | Finevask | Fulopin | Gensia | Gracivask | Gravask | Intervask | Licodipin | Lodipas | Lovask | Norvask | Opivask | Pehavask | Provask | Samcovask | Sandovask | Simvask | Stamotens | Tensivask | Vasgard | Zenicardo | Zevask;
(IE) Ireland: Amlist | Amlodipine | Amlodipine bluefish | Amlodipine teva | Istin | Istolde;
(IL) Israel: Amlow | Norvasc;
(IN) India: Aamin | Acord | Adipin | Adipine | Adopin | Adp | Aginal | Aglodepin | Am-5 | Amaday | Amanat | Amblock | Amcard | Amchek | Amdac | Amdepin | Amfirst | Amicardia | Amilip | Amizac | Amlan | Amlan s | Amleod | Amlibon | Amlin | Amlip | Amlo | Amloc | Amlocom | Amlocor | Amlod | Amlodac | Amlodipin aaa | Amlogard | Amlogen | Amlogold | Amloheart | Amlokath | Amlokind | Amlokos | Amlol | Amlomed | Amlona | Amlong | Amlopar | Amlopin | Amlopres | Amlopure | Amlorel | Amlosafe | Amlostat | Amlosun | Amlosyl | Amlot | Amlotrust | Amlotus | Amlovas | Amlovas-S | Amlovel | Amlovib | Amlovin | Amloz | Amo | Amodep | Ampin | Ampine | Amrap | Amsach | Amsure | Amtas | Amvasc | Amvio | Amwa | Amzak o.d. | Angicam | Angiguard | Asomex | Atopin | Avacard | Bamlo | Big dur | Biodipin | Bp Mide | Calchek | Camlek | Camlo | Camlodip | Card | Carvasc | Ccb | Corvadil | Defidin | Diavasc | Dip | Elpress | Emadine | Esam | Esamlo | Esamlovin | Esdil | Eslo | Espin | Klodip | Lama | Lodipin | Lopin | Lupidip | M l o | Malodip | Milopin | Myodura | Nicol | Nipidol | Numlo | Primodil | Redipil | S ampure | S amsort | S-Camlo | S-klodip | Samlodon | Samlokind | Samstar | Sitelodip | Stamlo | Stressban | Tamlod | Topdip | Truamil | Udp | Vamlo | Vanizolol | Wellamo;
(IQ) Iraq: Amlodepen | Awalodipin | Samadipine;
(IS) Iceland: Amlo;
(IT) Italy: Abis | Almidis | Amlodipina | Amlodipina acc | Amlodipina almus | Amlodipina Arrow | Amlodipina aurobindo | Amlodipina Awp | Amlodipina Bluefish | Amlodipina Doc | Amlodipina Doc Generici | Amlodipina EG | Amlodipina pharmeg | Amlodipina Sandoz | Amlodipina teva italia | Amlodipina zentiva | Amlonor | Amlopol | Antacal | Aristamid | Balarm | Krudipin | Losedin | Monopina | Natam | Norvasc | Pressac | Tensilene;
(JO) Jordan: Amlocard | Amlovas | Diplow | Lofral | Lowvasc | Vaznor;
(JP) Japan: Amlodin | Amlodipine | Amlodipine kyorin | Amlodipine NS | Amlodipine od sawai | Amlodipine od tyk | Amlodipine Ohara | Amlodipine Towa | Amlodipine tsuruhara | Norvasc;
(KE) Kenya: Adipin | Amax | Amdip | Amdocal | Amedin | Amlibon | Amlo denk | Amloas | Amlocare | Amlocian | Amlocip | Amlodawa | Amlodeal | Amlodin | Amlodine | Amlodip | Amlofine | Amlomark | Amlong | Amlopres | Amlosafe | Amlosin | Amlostar | Amlosun | Amlovas | Amlozest | Amolab | Amtas | Asomex | Camlodin | Esam | Eslo | Flamodip | Gencard | Kardam | Lofral | Norvasc | Primodil | Provask | Stamlo | Swamlo | Varinil | Vazkor;
(KR) Korea, Republic of: A dipine | A pine | Alonorva | Am | Ambes | Ambiz | Ambp | Amlo one | Amlobepine | Amlobesyl | Amlobetine | Amlobis | Amlocan | Amlocard | Amlock | Amloda | Amlodapine | Amlodi | Amlodigen | Amlodin | Amlodip | Amlodipine | Amlodipine huons | Amlodown | Amloem | Amlogood | Amloke | Amlol | Amlomax | Amlomesil | Amlomin | Amlonin | Amlopin | Amloril | Amlosk | Amlospin | Amlospine | Amlost | Amlostar | Amlosyl | Amloten | Amlova | Amnodin | Amodin | Amodipin | Amodipin s | Amopin | Amopine | Amotension | Ampibesyl | Ampidipine | Amrokan | Amvesc | Anitin | Anopine | Anydipine | Anytension | Anytin | Ard | Arodioin | Arodip | Aropin | Asyldopine | Aukodifin | Barodipine | Bc low | Beardipine S | Belopin | Berodipin | Besandropin | Besdipine | Besylopine | Calblock | Calbroc | Cmg Amlodipine | Cobisk | D.w amlodipine besylate | Daewoongbio amlodipine | Davidipine | Diadin | Diroba | Dirova | Dongsung amlodipine | Dongwha amlodipine besylate | E dipine | Easytension | Emdipin | Empidipine | Enydipine | Eudipine | Evasc | Everdipine | Finedipine | Haperten | Harodin | Huniz amlodipine maleate | I dipine | Ilvasc | J dipine | Kranos | Kukje amlodipine | Lopin | Loudipine | Lovasc | Lowdin | M lodipine | Medipin | Medipine | Melodipine | MyungMoon Amlodipine | Navanel | Neodropine | Neurophin | New amlodip | Newadin | Newdipin | Newsc | Newsdipine | Normaloc | Norvac | Norvaforce | Norvaloc | Norvasc | Norvatec | Nosk | Novacadin | Novacot | Novadic | Novadipin | Novagen | Novalopine | Novamopine | Novapin | Novascan | Novasphin | Novastin | Novatec | Novatension | Novatin | Novcapine | Novdipine | Octadipine | Orodipine | Prestin | Prodipine | Sandoz amlodipine | Selodipine | Seoul amlodipine besylate | Siamlopin | Sinnovapin | Skad | Skad b | Stadipin | Stardipine | Taiguk amlodipine | TDS Amlodipine Besylate | Unasc | Unibesyl | Uniropin | Urodipine | Varodipine | Varosc | Wydipine | Yungjin amlodipine;
(KW) Kuwait: Amlo | Amlocim | Amlozek | Amvaz | Istin | Lofral | Vascodipine;
(LB) Lebanon: Amdip | Amline | Amlo | Amlocard | Amlocim | Amlodipin Genericon | Amlodipine | Amlogal Divule | Amlorine | Amosarc | Cinopin | Torans;
(LT) Lithuania: Agen | Alneta | Amlocard | Amlodipin Medochemie | Amlodipin Teva | Amlodipine Accord | Amlodipine Ingen Pharma | Amlodipine vitabalans | Emlodin | Normodipine | Norvasc | Orkal | Stamlo | Tenox;
(LU) Luxembourg: Amlodipine Besilaat Sandoz;
(LV) Latvia: Agen | Amlocard | Amlodigamma | Amlodipin Medochemie | Amlodipin Olainfarm | Amlodipin Ratiopharm | Amlodipin Teva | Amlodipine Accord | Amlodipine vitabalans | Norvasc | Tenox;
(MA) Morocco: Amep | Amilo | Amlodipine | Amlodipine gt | Amlor | Amovas | Anglor | Calcinib | Dipicor | Dolpine | Inikal | Lorcard | Medep | Olmadip | Perovasc | Pimlo;
(MT) Malta: Vasorex;
(MX) Mexico: Adiuvo | Aken | Aldromasil | Ambel tec | Amlibon | Amlibon bes | Amlodipino | Amlodipino genetica | Amlodipino landsteiner | Amlodipino liomont | Amlodipino raam | Amtev | Angiodal | Apodino | Calantago | Cantry | Cardecal | Ccbcard | Collidipin | Cropinex | Eslodinepin | Invical | Juvalid | Lalpro | Lodicar | Lodicord | Nablody | Nordiver | Norpled | Norvas | Pequisy | Poltroon | Preslopin | Presone 1 | SBL Car | Sistopres | Spinodin | Stamlomex | Torlo | Tropad | Zadivonal | Zagapsol | Zaxinat;
(MY) Malaysia: Amcardia | Amcor | Amdepin | Amkline | Amlibon | Amlodac | Amlomed | Amlong | Amlopin | Amlopres | Amnoz | Amod | Amtas | Anlodin | Avevasc | Camlodin | Kardam | Lofral | Nordipine | Norvasc | Nulop | Primodil | Stadovas | Sunvasc | Tenox | Vamlo | Zynor;
(NG) Nigeria: Acedipin | Amcard | Amdepin | Amdocal | Amilod | Amlo | Amlodipine | Amlodipine besylate | Amloditop | Amloedge | Amloheal | Amlokris | Amlomed | Amlopril | Amlosam | Amlozest | Amnique | Ampine | Amzak | Anlodin | Asomex | Baropin | Bg vascol | Bpcon | Cadiprot | Chiram | Cladipine | Danlodip | Deno amlodipine | Dilopax | Diplovas | Dovipine | Eden | Eden amlodipine | Emzovasc | Esam | Everdestiny amlodipine | Glopam | Hevasc | Jaffkin amlodipine | Juvasc | K amlod | Lalit | Lopin | Maclodipine | Meem amlodipine | Miravasc | Nci amlodipine | Nelb amlodipine | Norvasc | Novaday | P one amlodipine | Pectovasc | Pemalod | Pharmamax amlodipine | Pilovas | Relodipin | Ritedipine | Ronybo amlodipine | Rotadipine | Rumapine | Swamlo | Tevasc | Triumvirate amlodipine | V bells amlodipine | Zyropin;
(NL) Netherlands: Amlodipine | Amlodipine (als besilaat) sandoz | Amlodipine A | Amlodipine Actavis | Amlodipine aurobindo | Amlodipine bluefish | Amlodipine CF | Amlodipine sandoz | Norvas | Norvasc;
(NO) Norway: Amlodipin | Amlodipin accord | Amlodipin actavis | Amlodipin bmm pharma | Amlodipin Copyfarm | Amlodipin hexal | Amlodipin Hexal | Amlodipin sandoz | Amlodipine vitabalans | Istin | Norvasc;
(NZ) New Zealand: Apo amlodipine | Calvasc | Norvasc | Vasorex;
(OM) Oman: Vascodipine;
(PA) Panama: Amlodipino vir pharma;
(PE) Peru: Alestol | Amdipin | Amidile g | Amlobiotech | Amlocar | Amlodipino | Amlodipress | Amlong | Amloprednil | Amlovas | Calchek | Coropine | Edemsoft | Finacal | Noloten | Norvasc | Olutan | Stamlo | Tensocard | Ximax;
(PH) Philippines: Acipta | Actapin | Aforbes | Alodine | Amaday | Amalvex | Ambesyl | Ambloc | Amdipine | Amilip | Amlion | Amlix | Amlobes | Amlocare | Amlocor | Amlodac | Amlodia | Amlodipine | Amlodipine Ritemed | Amlogen | Amlogin | Amlokard | Amlonex | Amlong | Amlopin | Amlopure | Amlorex | Amloric | Amlorika | Amlosyl | Amlothix | Amlotraz | Amlotrene | Amnique | Amnor | Amo | Amvalat | Amvasc BE | Angivasc | Aprenorm | Arcadia | Besilopin | Besylon | Bezam | Blocapast | Boie amlodipine besilate | Calbloc | Calcebis | Calcheck | Calvaso | Cardiovasc | Cardivasc | Cardol | Coram | Corvex | Covasc | Dailyvasc | Danlopin | Derox | Dilavasc | Emlip | Eodipine | Eurovasc | Exeldin | Godipine | Hartvasc | Hylodine | Hyperta | Johnvasc | Lodibes | Lodibiz | Lodicap | Lodicor | Lodipen | Lodiper | Lodipex | Medipin | Medivasc | Morvas | Nepidol | Norbloc | Norvac | Norvasc | Norvatrol | Odasyl | Omnivas | Philvasc | Prelod | Proamlo | Prodipine | Provasc | Rhea Amlodipine | Sainyo | Scilodipine | Sedipin | Swamlo | Sylodipine | Teneze | Varodipine | Vasalat | Vascar | Vaselec | Vaselon | Vasocar | Vasprim | Wilomax;
(PK) Pakistan: Adoptin | Alopine | Amdipine | Amdocal | Amdol | Amepine | Amilip | Aml | Amlis | Amlobest | Amlocard | Amlod | Amlodip | Amlonext | Amlopin | Amlosyd | Amlotac | Amlow | Amodip | Amolin | Ampress | Amrx | Anam | Angipin | Bescard | Ca-B | Cabok | Calbor | Caloc | Canta | Caprinza | Cardiosil | Cardiovasc | Coram | Corcont | Cordium | Corinor | Corsafe | Dipsan | Ephacard | G-sac | Hartvasc plus | Hodip | Hypercor | Hypernil | Hypotin | Hypress | Istin | Leaf | Lodipin | Lodopin | M Low | Medvasc | Megadip | Melody | Melopen | Miforec | Miosil | Modopine | Neopres | Norsap 5 | Norvasc | Onato | Pidol | Prescard | Quvasc | Ravapine | Revloc | Rydem | Salome | Securin | Sofvasc | Swint | Vaslopine | Vasodil | Vespin | Zamlo | Zeglopin | Zodip;
(PL) Poland: Adipine | Agen | Aldan | Almiden | Alneta | Amlaxopin | Amlodipine Aurobindo | Amlodipine Aurovitas | Amlodipine bluefish | Amlodipine Orion | Amlodipine teva | Amlodipine vitabalans | Amlodipinum Tad | Amlomyl | Amlonor | Amlopin | Amloratio | Amlozek | Apo amlo | Cardilopin | Damloc | Finamlox | Normodipine | Norvasc | Tenox | Vilpin;
(PR) Puerto Rico: Amlodipine besylate | Katerzia | Norliqva | Norvasc;
(PT) Portugal: Amlocor | Amlodipina | Amlodipina alter | Amlodipina aurobindo | Amlodipina aurovitas | Amlodipina basi | Amlodipina ciclum | Amlodipina Krka | Amlodipina Mibral | Amlodipina mylan | Amlodipina Parke-Davis | Amlodipina Ratiopharm | Amlodipina stada | Amlodipina zentiva | Cardionox | Drime | Mibral | Norvasc | Resines | Tensiovas;
(PY) Paraguay: Amlodipina cellofarm | Amlodipina dallas | Amlodipina dutriec | Amlodipina emcure | Amlodipina fda | Amlodipina rospaw | Amlodipino genfar | Amlodipino la sante | Amlodipino mintlab | Amlodipino sanderson | Amlodipino sandoz | Ampliron | Amze | Asomex | Besilato de amlodipino bioethic pharma | Cardiotonil | Corolar | Cuorexam | Hypoten | Inhical | Inihical | Lodinest | Lodipina | Noloten | Normopas | Normoten | Solen | Tensiocom | Terloc | Xaterol | Xaterol forte;
(QA) Qatar: Amlo | Amlocor | Amlodar | Amlogaran | Amopress | Amvasc | Duactin | Glodip | Hypodipine | Lotense | Lowrac | Lowvasc | Norvasc | Qvasc | Vascodipine;
(RO) Romania: Almacor | Almiden | Alozur | Amlo tad | Amlodigamma | Amlodipin al | Amlodipin vim spectrum | Amlodipina actavis | Amlodipina aurobindo | Amlodipina helcor | Amlodipina lph | Amlodipina terapia | Amlodipina zentiva | Amlodipine | Amlodipine medochemie | Amlodipine valeant | Amlohexal | Cardilopin | Eplodin | Norvasc | Recotens | Tardip | Tenox;
(RU) Russian Federation: Agen | Akridipin | Amlo | Amlodac | Amlodigamma | Amlodipharm | Amlodipin | Amlodipin agio | Amlodipin Cardio | Amlodipin Teva | Amlodipin Zentiva | Amlodipin zt | Amlodipine | Amlodipine agio | Amlodipine Alkaloid | Amlodipine alsi | Amlodipine besilat | Amlodipine biocom | Amlodipine borimed | Amlodipine Chaika Pharma | Amlodipine prana | Amlodipine reneval | Amlodipine sandoz | Amlodipine sanofi | Amlodipine teva | Amlodipine vertex | Amlodipine zentiva | Amlodipine zt | Amlodipine ZT | Amlodivel | Amlokard sanovel | Amlong | Amlonorm | Amlorus | Amlotop | Amlovas | Calchek | Cardilopin | Cordi cor | Cordy cor | Corvadil | Escordi cor | Karmagip | Normodipine | Normodivask | Norvadin | Norvasc | Omelar cardio | Stamlo | Stamlo M | Tenox | Vero amlodipine;
(SA) Saudi Arabia: Amep | Amlocard | Lodipam | Vascodipine;
(SE) Sweden: Amlarrow | Amlodipin accord | Amlodipin actavis | Amlodipin aurobindo | Amlodipin bluefish | Amlodipin bmm pharma | Amlodipin jubilant | Amlodipin krka | Amlodipin medical valley | Amlodipin Merck NM | Amlodipin mylan | Amlodipin orifarm | Amlodipin sandoz | Amlodipin stada | Amlodipin Zentiva | Amlodipine teva | Amlodipine vitabalans | Amlodistad | Amloratio | Amlori | Norvasc;
(SG) Singapore: Actapin | Amcardia | Amdhapine | Amlodipine sandoz | Amlong | Amlotens | Amtas | Anlodin | Apo amlodipine | Avevasc | Lodipin | Norvasc | Sunvasc | Swamlo | Tenox | Varodipine | Zynor;
(SI) Slovenia: Amlodipin Lek | Amlodipin Teva | Amlodipin vitabalans | Amlodipine | Amlopin | Norvasc | Tenox | Vilpin;
(SK) Slovakia: Agen | Amlodipin | Amlodipin Actavis | Amlodipin hbf | Amlodipin Orion | Amlodipin sandoz | Amlodipin vitabalans | Amlodipine bluefish | Amlopin | Amlozek | Apresa | Cardilopin | Genam | Normodipine | Norvasc | Tenox | Zamlodax;
(SL) Sierra Leone: Amlodipine;
(SR) Suriname: Amaday | Amlo denk | Amlodipine | Amlodipine Accord | Amlodipine Actavis | Amlodipine apotex | Amlodipine besylate | Amlodipine mylan | Amlonip | Amlopres | Amlopress | Amlorine | Amtas | Apo amlodipine | Asomex | Camlodin | Hovasc | Norvasc;
(TH) Thailand: Ambes | Amcardia | Amloc | Amlodac | Amlopine | Amlopress | Amvas | Deten | Lovas | Narvin | Norvasc;
(TN) Tunisia: Amlodep | Amlodipine medis | Amlodipine winthrop | Amlodis | Amlor | Lodepine | Lodipex | Mibral;
(TR) Turkey: Amlodis | Amlohex | Amlokard | Amlovas | As Amlo | Dilopin | Lipinox | Modipin | Monovas | Nipidol | Norlopin | Normopres | Norvadin | Norvasc | Penvasc | Vasocard | Vazkor;
(TW) Taiwan: Alopine | Amcopine | Amilo | Amlo | Amlobin | Amlodac | Amlodine | Amlodipine | Amlodipine sandoz | Amlos | Amlosin | Amndiline | Amopine | Calnelpress | Cinopin | Cinsuton | Du.Q | Lodipine | Lolate | Nobar | Nordipine | Norvasc | Taishunmai | Yawaho;
(UA) Ukraine: Agen | Aladin | Amlo | Amlocim | Amlocor | Amlodex | Amlodin | Amlodipin | Amlodipin darnitsa | Amlodipin kv | Amlodipine | Amlodipine euro | Amlodipine pfizer | Amlodipine sandoz | Amlodipine teva | Amlokard sanovel | Amlong | Amlopin | Amlopril | Amlosandoz | Amlovas | Amlovel | Emlodin | Normodipin | Norvasc | Semlopin | Stamlo | Vasodipin;
(UG) Uganda: Amlibon | Amlo denk | Amlo h | Amloas | Amlong | Amlopress | Amlotrust | Amlovas | Amtas | Anlodin | Asomex | Cardiosan | Cardipac | Coram | Corvadil | Derox | Kardam | Lopicard | Primodil | Vazkor | Ziflodip;
(UY) Uruguay: Amlodipina | Amlodipina Ivax | Amlodipina regueiro | Amlodipino sandoz | Amlopress | Ampliron | Amxel | Angiostabil | Cordiax | Ilduc | Norvasc | Tensofin | Terloc;
(VE) Venezuela, Bolivarian Republic of: Ambiodipina | Amipina | Amlibon | Amloc | Amlodipina | Amlodipino | Amlopin | Amlovas | Amval | Angiovan | Cab | Carpin | Dilotex | Lodipin | Medlo | Nilam | Norvasc | Pinam | Stamlo | Unidoscor | Vasocal;
(VN) Viet Nam: Amloboston | Amlodipin Domesco | Amlodipine stella | Amlothope | Bluepine | Cardivasor | Kavasdin | Lodimax | Pymealong | Remedipin;
(YE) Yemen: Amlodak;
(ZA) South Africa: Adco norpene | Almadin | Amlate | Amloc | Amlodipine biotech | Amlodipine unicorn | Amlodipine unimed | Amlodipine Winthrop | Amtas | Aprate | Austell amlodipine | Ciplavasc | Corvadil | Cpl alliance amlodipine | Gulf amlodipine | Indo amlodipine | Keysal | Klodip | Lomanor | Norcard | Nortwin | Norvasc | Pendine | Sandoz amlodipine | Stamlo;
(ZM) Zambia: Amdepin | Amlo denk | Amlo h | Amlodac | Amlodipine | Amlovas | Amlowin | Amlox | Amtas | Asomex | Corvadil | Esam | Flamodip | Kardam | Klodip | Lomanor | Norvasc | Primodil | Varinil;
(ZW) Zimbabwe: Amlin | Amlo h | Amlocor | Amlopres | Amlovar | Amlovasc | Corvadil | Lomanor | Norvasc

Abernethy DR. The pharmacokinetic profile of amlodipine. Am Heart J. 1989;118(5 pt 2):1100-1103. doi:10.1016/0002-8703(89)90834-x [PubMed 2530866]
Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. J Pediatr. 2001;139(2):317-319. [PubMed 11487763]
Ahn HK, Nava-Ocampo AA, Han JY, et al, "Exposure to Amlodipine in the First Trimester of Pregnancy and During Breastfeeding," Hypertens Pregnancy, 2007, 26(2):179-87. doi:10.1080/10641950701204554 [PubMed 17469008]
Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-597. [PubMed 3960626]
American Academy of Pediatrics Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. Pediatrics. 1997;99(2):268-278. [PubMed 9024461]
American College of Obstetricians and Gynecologists (ACOG). ACOG practice bulletin no. 203: chronic hypertension in pregnancy. Obstet Gynecol. 2019;133(1):e26-e50. doi:10.1097/AOG.0000000000003020 [PubMed 30575676]
Andersen J, Groshong T, Tobias JD. Preliminary experience with amlodipine in the pediatric population. Am J Ther. 2006;13(3):198-204. doi:10.1097/01.mjt.0000147593.73888.d5 [PubMed 16772760]
Anderson PO, Sauberan JB. Modeling drug passage into human milk. Clin Pharmacol Ther. 2016;100(1):42-52. doi: 10.1002/cpt.377. [PubMed 27060684]
Aoki H, Ito N, Kaniwa N, et al. Low levels of amlodipine in breast milk and plasma. Breastfeed Med. 2018;13(9):622-626. [PubMed 30265578]
Arasan SN, Yenigun EC, Cevher SK, Dede F. Amlodipine induced massive ascites, a rare clinical case. Iran J Kidney Dis. 2020;14(6):517-519. [PubMed 33277458]
Aronow WS, Fleg JL, Pepine CJ, et al, “ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,” Circulation, 2011, 123(21):2434-506. [PubMed 21518977]
Baetz BE, Patton ML, Guilday RE, Reigart CL, Ackerman BH. Amlodipine-induced toxic epidermal necrolysis. J Burn Care Res. 2011;32(5):e158-e160. doi:10.1097/BCR.0b013e31822ac7be [PubMed 21772148]
Bankhead R, Boullata J, Brantley S, et al. Enteral nutrition practice recommendations. JPEN J Parenter Enteral Nutr. 2009;33(2):122-167. doi:10.1177/0148607108330314 [PubMed 19171692]
Belch J, Carlizza A, Carpentier PH, et al. ESVM guidelines - the diagnosis and management of Raynaud's phenomenon. Vasa. 2017;46(6):413-423. doi: 10.1024/0301-1526/a000661. [PubMed 28895508]
Biston P, Mélot C, Degaute JP, et al. Prolonged antihypertensive effect of amlodipine: a prospective double-blind randomized study. Blood Press. 1999;8(1):43-48. [PubMed 10412882]
Boullata JI. Enteral medication for the tube-fed patient: making this route safe and effective. Nutr Clin Pract. 2021;36(1):111-132. doi:10.1002/ncp.10615. [PubMed 33373487]
Boullata JI. Guidebook on Enteral Medication Administration. American Society for Parenteral and Enteral Nutrition; 2019.
Boullata JI, Carrera AL, Harvey L, et al. ASPEN safe practices for enteral nutrition therapy. JPEN J Parenter Enteral Nutr. 2017;41(1):15-103. doi:10.1177/0148607116673053 [PubMed 27815525]
Bozbas SS, Bozbas H. Portopulmonary hypertension in liver transplant candidates. World J Gastroenterol. 2016;22(6):2024-2029. doi:10.3748/wjg.v22.i6.2024 [PubMed 26877607]
Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. MMWR Morb Mortal Wkly Rep. 1982;31(22):290-291. http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm [PubMed 6810084]
Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. MMWR Morb Mortal Wkly Rep. 1984;33(14):198-199. http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm [PubMed 6423951]
Cífková R, Johnson MR, Kahan T, et al. Peripartum management of hypertension: a position paper of the ESC Council on Hypertension and the European Society of Hypertension. Eur Heart J Cardiovasc Pharmacother. 2020;6(6):384-393. doi:10.1093/ehjcvp/pvz082 [PubMed 31841131]
Cornes PG, Hole AC. Amlodipine gynaecomastia. Breast. 2001;10(6):544-545. doi:10.1054/brst.2001.0308 [PubMed 14965638]
Cvetković Z, Suvajdžić-Vuković N, Todorović Z, Panić M, Nešković A. Simvastatin and amlodipine induced thrombocytopenia in the same patient: double trouble and a literature review. J Clin Pharm Ther. 2013;38(3):246-248. doi:10.1111/jcpt.12051 [PubMed 23442182]
Darnis F, Poupon R. Pharmacokinetics and safety of single oral doses of amlodipine in patients with and without hepatic impairment: an open study. Int J Clin Pharmacol Res. 1993;13(1):29-33. [PubMed 8509234]
Demirci H, Polat Z, Kantarcioglu M, Kekilli M, Uygun A, Bagci S. Short-term amlodipine induced liver injury : an extremely rare acute complication. Acta Gastroenterol Belg. 2013;76(4):441. [PubMed 24592551]
Donnelly R, Meredith PA, Miller SH, et al. Pharmacodynamic modeling of the antihypertensive response to amlodipine. Clin Pharmacol Ther. 1993;54(3):303-310. [PubMed 8375125]
Doyle GD, Donohue J, Carmody M, Laher M, Greb H, Volz M. Pharmacokinetics of amlodipine in renal impairment. Eur J Clin Pharmacol. 1989;36(2):205-208. [PubMed 2524389]
Dressler D. Tardive dystonic syndrome induced by the calcium-channel blocker amlodipine. J Neural Transm (Vienna). 2014;121(4):367-369. doi:10.1007/s00702-013-1108-8 [PubMed 24169926]
Egbuonu F, Zazal B, Atwan M, Davies A. Rare case of amlodipine induced hepatitis: a case report. J Med Therap. 2019;3:1-2.doi:10.15761/JMT.1000142
Ejaz AA, Fitzpatrick PM, Haley WE, Wasiluk A, Durkin AJ, Zachariah PK. Amlodipine besylate induced acute interstitial nephritis. Nephron. 2000;85(4):354-356. [PubMed 10940749]
Expert opinion. Senior Enteral Feeding Tube Editorial Team: Joseph I. Boullata, PharmD, RPh, CNS-S, FASPEN, FACN; Peggi A. Guenter, PhD, RN, FASPEN; Kathleen Gura, PharmD, BCNSP, FASHP, FASPEN, FPPA, FMSHP; Mark G. Klang, MS, RPh, BCNSP, PhD, FASPEN; Linda Lord, NP, ACNP-BC, CNSC, FASPEN.
Expert opinion. Senior Hepatic Editorial Team: Matt Harris, PharmD, MHS, BCPS, FAST, FCCP; Jeong Park, PharmD, MS, BCTXP, FCCP, FAST; Arun Jesudian, MD; Sasan Sakiani, MD.
Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.
Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics. 2017;140(3). [PubMed 28827377]
Flynn JT and Pasko DA, “Calcium Channel Blockers: Pharmacology and Place in Therapy of Pediatric Hypertension,” Pediatr Nephrol, 2000, 15(3-4):302-16. [PubMed 11149130]
Flynn JT, Nahata MC, Mahan JD Jr, Portman RJ; PATH-2 Investigators. Population pharmacokinetics of amlodipine in hypertensive children and adolescents. J Clin Pharmacol. 2006;46(8):905-916. [PubMed 16855075]
Flynn JT, Newburger JW, Daniels SR, et al, "A Randomized, Placebo-Controlled Trial of Amlodipine in Children With Hypertension," J Pediatr, 2004, 145(3):353-9. [PubMed 15343191]
Flynn JT, Smoyer WE, and Bunchman TE, “Treatment of Hypertensive Children With Amlodipine,” Am J Hypertens, 2000a, 13(10):1061-6. [PubMed 11041159]
Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061. [PubMed 26934393]
Gargh K, Baildam EM, Cleary GA, Beresford MW, McCann LJ. A retrospective clinical analysis of pharmacological modalities used for symptomatic relief of Raynaud's phenomenon in children treated in a UK paediatric rheumatology centre. Rheumatology (Oxford). 2010;49(1):193‐194. [PubMed 19797310]
Gouveia R, Veiga H, Costa AA, Pereira J, Lourenço P. Bradycardia, renal failure, atrioventricular nodal blockade, shock, and hyperkalemia syndrome due to amlodipine: a case report of an underdiagnosed medical condition. Cureus. 2022;14(1):e21144. doi:10.7759/cureus.21144. [PubMed 35165595]
Hammerstrom AE. Possible amlodipine-induced hepatotoxicity after stem cell transplant. Ann Pharmacother. 2015;49(1):135-139. doi:10.1177/1060028014552820 [PubMed 25239629]
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063 [PubMed 35363499]
Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47(5):312-313. [PubMed 12534540]
Ito S. Drug therapy for breast-feeding women [published correction appears in N Engl J Med. 2000;343(18):1348]. N Engl J Med. 2000;343(2):118-126. doi:10.1056/NEJM200007133430208 [PubMed 10891521]
Jamerson K, Weber MA, Bakris GL, et al; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417-2428. doi: 10.1056/NEJMoa0806182. [PubMed 19052124]
James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-520. [PubMed 24352797]
John K, Mishra AK, Gunasekaran K, Iyyadurai R. Amlodipine-induced gingival hyperplasia in a young male with stage 5 chronic kidney disease. Case Rep Nephrol. 2020;7801546. doi:10.1155/2020/7801546. [PubMed 32099704]
Josefsson M, Zackrisson AL, and Ahlner J, “Effect of Grapefruit Juice on the Pharmacokinetics of Amlodipine in Healthy Volunteers,” Eur J Clin Pharmacol, 1996, 51(2):189-93. [PubMed 8911887]
Juraschek SP, Simpson LM, Davis BR, Beach JL, Ishak A, Mukamal KJ. Effects of antihypertensive class on falls, syncope, and orthostatic hypotension in older adults: The ALLHAT Trial. Hypertension. 2019;74(4):1033-1040. doi:10.1161/HYPERTENSIONAHA.119.13445 [PubMed 31476905]
Katerzia (amlodipine) oral suspension [prescribing information]. Woburn, MA: Azurity Pharmaceuticals Inc; April 2023.
Katerzia (amlodipine) oral suspension [prescribing information]. Woburn, MA: Azurity Pharmaceuticals Inc; April 2023.
Khattak S, Rogan JW, Saunders EF, et al, “Efficacy of Amlodipine in Pediatric Bone Marrow Transplant Patients,” Clin Pediatr (Phila), 1998, 37(1):31-5. [PubMed 9475697]
Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021;99(3S):S1-S87. doi:10.1016/j.kint.2020.11.003 [PubMed 33637192]
Klang MG. Developing guidance for feeding tube administration of oral medications. JPEN J Parenter Enteral Nutr. 2023;47(4):519-540. doi:10.1002/jpen.2490 [PubMed 36847617]
Kliegman RM and St. Geme J, eds. Nelson Textbook of Pediatrics. 21st ed. Philadelphia, PA: Saunders Elsevier; 2020.
Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327‐1339. [PubMed 27941129]
Kungys G, Naujoks H, Wanner C. Pharmacokinetics of amlodipine in hypertensive patients undergoing haemodialysis. Eur J Clin Pharmacol. 2003;59(4):291-295. [PubMed 12845505]
Lafuente NG. Calcium channel blockers and hepatotoxicity. Am J Gastroenterol. 2000;95(8):2145. doi:10.1111/j.1572-0241.2000.02223.x [PubMed 10950093]
Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43(3):172. [PubMed 10985636]
Magee LA, Smith GN, Bloch C, et al. Guideline No. 426: hypertensive disorders of pregnancy: diagnosis, prediction, prevention, and management. J Obstet Gynaecol Can. 2022;44(5):547-571.e1. doi:10.1016/j.jogc.2022.03.002 [PubMed 35577426]
Makani H, Bangalore S, Romero J, et al. Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate--a meta-analysis of randomized trials. J Hypertens. 2011;29(7):1270-1280. doi:10.1097/HJH.0b013e3283472643 [PubMed 21558959]
Mann JFE, Flack JM. Hypertension in adults: Initial drug therapy. Connor RF, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed March 7, 2023.
Meredith PA and Elliott HL, "Clinical Pharmacokinetics of Amlodipine," Clin Pharmacokinet, 1992, 22(1):22-31. [PubMed 1532771]
Mizuta T, Kato M. Amlodipine-induced subacute cutaneous lupus erythematosus localized to non-sun-exposed areas. Case Rep Dermatol. 2022;14(1):71-76. doi:10.1159/000524001. [PubMed 35496508]
Morgan JL, Kogutt BK, Meek C, et al. Pharmacokinetics of amlodipine besylate at delivery and during lactation. Pregnancy Hypertens. 2018;11:77-80. [PubMed 29523279]
Morgan JL, Kogutt BK, Meek C et al. Pharmacokinetics of amlodipine besylate during pregnancy-how much infant exposure occurs? Am J Obstet Gynecol. 2017;216:S515-S516.
Nahapetian A, Oudiz RJ. Serial hemodynamics and complications of pregnancy in severe pulmonary arterial hypertension. Cardiology. 2008;109(4):237-240. [PubMed 17873487]
Naito T, Kubono N, Deguchi S, et al. Amlodipine passage into breast milk in lactating women with pregnancy-induced hypertension and its estimation of infant risk for breastfeeding. J Hum Lact. 2015a;31(2):301-306. doi: 10.1177/0890334414560195. [PubMed 25447596]
Naito T, Kubono N, Ishida T, et al. CYP3A activity based on plasma 4β-hydroxycholesterol during the early postpartum period has an effect on the plasma disposition of amlodipine. Drug Metab Pharmacokinet. 2015b;30(6):419-424. doi: 10.1016/j.dmpk.2015.08.008. [PubMed 26654672]
National Heart, Lung, and Blood Institute. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, Clinical Practice Guidelines, 2011, National Institutes of Health. Available at http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf
National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, "The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents," Pediatrics, 2004, 114(2 Suppl 4th Report):555-76. [PubMed 15286277]
National Institute for Health and Care Excellence (NICE). Hypertension in pregnancy: diagnosis and management. NICE guideline, No. 133. http://www.nice.org.uk/guidance/ng133. Published June 25, 2019. Accessed December 1, 2022.
Niemiec PW Jr, Vanderveen TW, Morrison JI, Hohenwarter MW. Gastrointestinal disorders caused by medication and electrolyte solution osmolality during enteral nutrition. JPEN J Parenter Enteral Nutr. 1983;7(4):387-389. doi:10.1177/0148607183007004387 [PubMed 6413718]
Norliqva (amlodipine) [prescribing information]. Farmville, NC: CMP Pharma Inc; February 2022.
Norvasc (amlodipine) [prescribing information]. New York, NY: Pfizer; February 2023.
Norvasc (amlodipine) [product monograph]. Etobicoke, Ontario, Canada: BGP Pharma ULC; August 2023.
O'Mahony D, Cherubini A, Guiteras AR, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 3. Eur Geriatr Med. 2023;14(4):625-632. doi:10.1007/s41999-023-00777-y [PubMed 37256475]
Ommen SR, Ho CY, Asif IM, et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(23):e1239-e1311. doi:10.1161/CIR.0000000000001250 [PubMed 38718139]
Packer M, Carson P, Elkayam U, et al; PRAISE-2 Study Group. Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (prospective randomized amlodipine survival evaluation 2). JACC Heart Fail. 2013;1(4):308-314. doi: 10.1016/j.jchf.2013.04.004. [PubMed 24621933]
Packer M, O'Connor CM, Ghali JK, et al, “Effect of Amlodipine on Morbidity and Mortality in Severe Chronic Heart Failure. Prospective Randomized Amlodipine Survival Evaluation Study Group,” N Engl J Med, 1996, 335(15):1107-14. [PubMed 8813041]
Parker ML, Robinson RF, and Nahata MC, “Amlodipine Therapy in Pediatric Patients With Hypertension,” J Am Pharm Assoc, 2002, 42(1):114-7. [PubMed 11833502]
pdp-Amlodipine [product monograph]. Montreal, Quebec, Canada: Pendopharm, Division of Pharmascience Inc; March 2021.
Pedrinelli R, Dell'Omo G, Mariani M. Calcium channel blockers, postural vasoconstriction and dependent oedema in essential hypertension. J Hum Hypertens. 2001;15(7):455-461. doi:10.1038/sj.jhh.1001201 [PubMed 11464254]
Pedrinelli R, Dell'Omo G, Melillo E, Mariani M. Amlodipine, enalapril, and dependent leg edema in essential hypertension. Hypertension. 2000;35(2):621-625. doi:10.1161/01.hyp.35.2.621 [PubMed 10679507]
Pfammatter JP, Clericetti-Affolter C, Truttmann AC, et al, “Amlodipine Once-Daily in Systemic Hypertension,” Eur J Pediatr, 1998, 157(8):618-21. [PubMed 9727842]
Refer to manufacturer’s labeling.
Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018;39(34):3165-3241. doi:10.1093/eurheartj/ehy340 [PubMed 30165544]
Rogan JW, Lyszkiewicz DA, Blowey D, et al, “A Randomized Prospective Crossover Trial of Amlodipine in Pediatric Hypertension,” Pediatr Nephrol, 2000, 14(12):1083-7. [PubMed 11045391]
Rosendorff C, Lackland DT, Allison M, et al. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. J Am Coll Cardiol. 2015;65(18):1998-2038. doi:10.1016/j.jacc.2015.02.038 [PubMed 25840655]
Schetz D, Kocić I. A new adverse drug reaction--Schamberg's disease caused by amlodipine administration--a case report. Br J Clin Pharmacol. 2015;80(6):1477-1478. doi:10.1111/bcp.12742 [PubMed 26256559]
Scholz H. Pharmacological aspects of calcium channel blockers. Cardiovasc Drugs Ther. 1997;10:869-872. [PubMed 9126675]
Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8980):1312-1313. [PubMed 7746084]
Silverstein DM, Palmer J, Baluarte HJ, et al, “Use of Calcium-Channel Blockers in Pediatric Renal Transplant Recipients,” Pediatr Transplant, 1999, 3(4):288-92. [PubMed 10562973]
Song G, Yoon HY, Yee J, Kim MG, Gwak HS. Antihypertensive drug use and psoriasis: a systematic review, meta- and network meta-analysis. Br J Clin Pharmacol. Published online October 5, 2021. doi:10.1111/bcp.15060 [PubMed 34611920]
Taguchi R, Naito T, Kubono N, Ogawa N, Itoh H, Kawakami J. Relationships between endogenous CYP3A markers and plasma amlodipine exposure and metabolism in early postpartum and non-peripartum women with hypertension. Pregnancy Hypertens. 2019;17:209-215. doi:10.1016/j.preghy.2019.07.002 [PubMed 31487643]
Tallian KB, Nahata MC, Turman MA, et al, “Efficacy of Amlodipine in Pediatric Patients With Hypertension,” Pediatr Nephrol, 1999, 13(4):304-10. [PubMed 10454779]
Teive HA, Germiniani FM, Werneck LC. Parkinsonian syndrome induced by amlodipine: case report. Mov Disord. 2002;17(4):833-835. doi:10.1002/mds.10185 [PubMed 12210888]
Vasa R, Martha Ramirez M. Abstracts of the Academy of Breastfeeding Medicine 18th Annual International Meeting. Amlodipine exposure through breastfeeding in a 32 week preterm newborn. Philadelphia, Pennsylvania, USA. November 21-24, 2013. Breastfeed Med. 2013;(8 suppl):S2-22. doi:10.1089/bfm.2013.9982 [PubMed 24188181]
Vincent J, Harris SI, Foulds G, et al, “Lack of Effect of Grapefruit Juice on the Pharmacokinetics and Pharmacodynamics of Amlodipine,” Br J Clin Pharmacol, 2000, 50(5):455-63. [PubMed 11069440]
Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023;148(9):e9-e119. doi:10.1161/CIR.0000000000001168 [PubMed 37471501]
von Vigier RO, Franscini LM, Bianda ND, et al, "Antihypertensive Efficacy of Amlodipine in Children With Chronic Kidney Diseases," J Hum Hypertens, 2001, 15(6):387-91. [PubMed 11439313]
Vukadinović D, Scholz SS, Messerli FH, et al. Peripheral edema and headache associated with amlodipine treatment: a meta-analysis of randomized, placebo-controlled trials. J Hypertens. 2019;37(10):2093–2103. doi:10.1097/HJH.0000000000002145 [PubMed 31107359]
Weber MA, Schiffrin EL, White WB, et al, Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich). 2014;16(1):14-26. [PubMed 24341872]
Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [published correction appears in Hypertension. 2018;71(6):e140-e144]. Hypertension. 2018;71(6):e140-e144. doi: 10.1161/HYP.0000000000000065. [PubMed 29133356]
White R, Bradnam V; British Pharmaceutical Nutrition Group. Handbook of Drug Administration via Enteral Feeding Tubes. 3rd ed. Pharmaceutical Press; 2015.
Wigley FM. Treatment of Raynaud phenomenon: Initial management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed January 31, 2020.
Wigley FM, Herrick AL, Flavahan NA, eds. Raynaud's Phenomenon: A Guide to Pathogenesis and Treatment. New York, NY: Springer; 2015.
Yu P, Diao W, Tang Q, Jiang X. A successful pregnancy and parturition in a patient with anuria undergoing maintenance hemodialysis for 6 years: a case report of a 3-year-follow-up. BMC Pregnancy Childbirth. 2015;15:218. doi: 10.1186/s12884-015-0642-9. [PubMed 26370296]
Zinsser P, Meyer-Wyss B, Rich P. Hepatotoxicity induced by celecoxib and amlodipine. Swiss Med Wkly. 2004;134(13-14):201. [PubMed 15106034]

Topic 12603 Version 823.0

خرید پکیج

Amlodipine: Pediatric drug information